natgillin/translations-raw huggingface dataset:
In the period from 90 days after rash onset to the end of follow-up, there was a 57% reduction in the severity-by-duration score (average scores of 347 for ZOSTAVAX and 805 for placebo; p=0.016). 
V obdobju od 90 dni po pojavu izpuščaja do konca obdobja spremljanja se je rezultat jakost-trajanje zmanjšal za 57 % (srednji rezultat 347 za cepivo ZOSTAVAX in 805 za placebo; p = 0,016).
Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6). 
Poleg tega ženska ne sme zanositi 1 mesec po cepljenju (glejte poglavje 4.6).
Vaccine-related serious adverse reactions were reported for 0.01% subjects vaccinated with ZOSTAVAX and subjects who received placebo. 
O resnih neželenih učinkih, povezanih s cepivom, so poročali pri 0,01 % oseb, cepljenih s cepivom ZOSTAVAX, in oseb, ki so prejele placebo.
After reconstitution, 1 dose (0.65 mL) contains: 
Po rekonstituciji 1 odmerek (0,65 ml) vsebuje:
Marketing Authorisation Holder: MSD VACCINS, 162 avenue Jean Jaurès, 69007 Lyon, France 
Imetnik dovoljenja za promet s cepivom: MSD VACCINS, 162 avenue Jean Jaurès, 69007 Lyon, Francija
In the vaccine group, the risk of developing PHN after zoster was 9 % (27/315), while in the placebo group it was 13 % (80/642). 
V skupini, ki je prejela cepivo, je bilo tveganje za pojav PHN po herpesu zostru 9 % (27/315), v skupini, ki je prejela placebo, pa 13 % (80/642).
Although, ZOSTAVAX is indicated as a single dose regimen (see section 4.2), a two-dose regimen was used. 
Čeprav je cepivo ZOSTAVAX indicirano v enem odmerku (glejte poglavje 4.2), sta bila uporabljena dva odmerka.
The STPS was initiated to accrue additional information on the persistence of vaccine efficacy for subjects who received ZOSTAVAX in SPS. 
Podštudija STPS je bila izvedena, da bi pridobili dodatne informacije o trajanju učinkovitosti cepiva pri osebah, ki so prejele cepivo ZOSTAVAX v študiji SPS.
Immunocompromised subjects The vaccine has not been studied in subjects with impaired immunity. 
Imunokomprimirane osebe Cepiva pri osebah s pomanjkljivo imunostjo niso preučevali.
• if you have been told by your doctor that you have a weakened immune system as a result of a disease, medicines, or other treatment 
• če vam je zdravnik povedal, da imate zaradi bolezni, zdravil ali drugih oblik zdravljenja oslabljen imunski sistem,
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder. 
Za vse morebitne nadaljnje informacije o tem cepivu se lahko obrnete na predstavništvo imetnika dovoljenja za promet s cepivom:
The risk of transmitting the attenuated vaccine virus from a vaccinee to a susceptible contact should be weighed against the risk of developing natural zoster and potentially transmitting wild-type VZV to a susceptible contact. 
Pretehtati je treba tveganje za prenos oslabljenega cepilnega virusa s cepljene osebe na dovzetne osebe, ki so bile v stiku s cepljeno osebo, in tveganje za pojav naravnega herpesa zostra ter možen prenos divjega tipa VZV na dovzetne osebe.
The most common adverse reactions reported in pivotal clinical trials were injection-site reactions. 
Najpogostejši neželeni učinki, o katerih so poročali v ključnih kliničnih preskušanjih, so bili reakcije na mestu injiciranja.
The needle should be pushed into the extremity of the syringe and rotated a quarter of a turn (90) to secure the connection. 
Iglo morate potisniti na konico brizge in jo obrniti za četrt obrata (90 º), da je pravilno nameščena.
Concomitant administration 
Sočasna uporaba
After you have had chickenpox, the virus that caused it stays in your body in nerve cells. 
Po prebolelih noricah njihov povzročitelj (virus) ostane v telesu v živčnih celicah.
ZOSTAVAX contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'. 
Cepivo ZOSTAVAX vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
ZOSTAVAX powder for injection SC/IM 
ZOSTAVAX prašek za injiciranje s.c./i.m.
It is unknown whether VZV is secreted in human milk. 
Ni znano, ali se VZV izloča v materino mleko.
The vaccine should under no circumstances be injected intravascularly. 
Cepiva ne smete nikoli injicirati intravaskularno.
Of the 295 ZOSTAVAX recipients, one case of serious vaccine related maculo-papular rash was reported on Day 4 following Dose 1 of ZOSTAVAX (see section 4.3). 
Med 295 prejemniki cepiva ZOSTAVAX so poročali o enem resnem primeru makulopapuloznega izpuščaja, povezanega s cepivom, in sicer 4. dan po 1. odmerku cepiva ZOSTAVAX (glejte poglavje 4.3).
In clinical trials with ZOSTAVAX, transmission of the vaccine virus has not been reported. 
Med kliničnim preskušanjem cepiva ZOSTAVAX o prenosu cepilnega virusa niso poročali.
If you have a blood clotting disorder or low levels of platelets in your blood, the injection will be given under the skin. 
Če imate motnjo strjevanja krvi ali nizko raven trombocitov v krvi, vam bodo cepivo injicirali pod kožo.
† The zoster pain BOI score is a composite score that incorporates the incidence, severity, and duration of acute and chronic zoster-associated pain over a 6 month follow-up period. 
† Ocena BOI bolečine zaradi herpesa zostra je sestavljena ocena, ki vključuje pojavnost, izrazitost in trajanje akutnih in kroničnih bolečin zaradi herpesa zostra v 6-mesečnem obdobju spremljanja.
However in a US effectiveness cohort study of 35,025 adults ≥ 60 years old, no increased risk of herpes zoster was observed in individuals who received ZOSTAVAX and 23-valent pneumococcal polysaccharide vaccine concomitantly (n=16,532) as compared to individuals receiving ZOSTAVAX one month to one year after 23-valent pneumococcal polysaccharide vaccine (n=18,493) in routine practice. 
Toda v ameriški kohortni študiji učinkovitosti pri 35.025 odraslih, starih ≥ 60 let, v kateri so posamezniki sočasno prejeli cepivo ZOSTAVAX in 23-valentno pnevmokokno polisaharidno cepivo (n = 16.532), niso opazili večjega tveganja za herpes zoster kot pri posameznikih, ki so prejeli cepivo ZOSTAVAX od enega meseca do enega leta po 23-valentnem pnevmokoknem polisaharidnem cepivu (n = 18.493) v rutinski praksi.
ZOSTAVAX was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications (See Immunogenicity). 
Dokazano je bilo, da cepivo ZOSTAVAX poživi imunost, specifično za VZV, kar je domnevno mehanizem, s katerim ščiti pred herpesom zostrom in njegovimi komplikacijami (glejte Imunogenost).
What ZOSTAVAX looks like and contents of the pack 
Izgled cepiva ZOSTAVAX in vsebina pakiranja
Subjects with severe thrombocytopenia or any other coagulation disorder were excluded. 
Izključene so bile osebe s hudo trombocitopenijo ali kakršno koli drugo motnjo strjevanja krvi.
The adjusted hazard ratio comparing the incidence rate of HZ in the two groups was 1.04 (95% CI, 0.92, 1.16) over a median follow-up of 4.7 years. 
Prilagojeno razmerje ogroženosti v primerjavi deležev pojavnosti HZ v obeh skupinah je bilo med mediano 4,7-letnim spremljanjem 1,04 (95 % IZ: 0,92 do 1,16).
However, post-marketing experience with varicella vaccines suggests that transmission of vaccine virus may occur rarely between vaccinees who develop a varicella-like rash and susceptible contacts [for example, varicella-zoster virus (VZV) susceptible infant grandchildren]. 
Izkušnje s cepivi proti noricam iz obdobja trženja pa kažejo, da lahko v redkih primerih pride do prenosa cepilnega virusa s cepljene osebe, pri kateri se je pojavil noricam podoben izpuščaj, na dovzetno osebo, ki je bila v stiku s cepljeno osebo [na primer za okužbo z VZV (varicella-zoster virus) dovzetni otroci].
ZOSTAVAX is used to vaccinate individuals 50 years of age or older. 
Cepivo ZOSTAVAX se uporablja za cepljenje oseb, starih 50 let ali več.
However, among vaccinated individuals who developed PHN, ZOSTAVAX significantly reduced PHN-associated (chronic) pain compared with placebo. 
Vendar pa je med cepljenimi posamezniki, pri katerih se je pojavila PHN, cepivo ZOSTAVAX pomembno zmanjšalo s PHN povezano (kronično) bolečino v primerjavi s placebom.
Hypersensitivity reactions including anaphylactic reactions 
Bolezni imunskega sistema preobčutljivostne reakcije, vključno z anafilaktičnimi reakcijami redki
ZOSTAVAX can be administered at the same time as inactivated influenza vaccine. 
Cepivo ZOSTAVAX se lahko daje sočasno s cepivi proti gripi z inaktiviranimi virusi.
The Oka/Merck strain of VZV was not detected from any specimens in SPS or ZEST. 
Seva VZV Oka/Merck niso zaznali v nobenem vzorcu v študijah SPS ali ZEST.
ZOSTAVAX is not indicated for treatment of zoster or PHN. 
Cepivo ZOSTAVAX ni indicirano za zdravljenje herpesa zostra ali PHN.
The general safety profiles of the SC and IM routes were otherwise comparable, but injection-site adverse reactions were significantly less frequent in the IM group (34%) compared with the SC group (64%). 
Splošna varnostna profila sta bila pri subkutani in intramuskularni uporabi primerljiva, vendar so bili neželeni učinki na mestu injiciranja pri intramuskularni uporabi (34 %) značilno manj pogosti kot pri subkutani (64 %).
1, Oka/Merck strain, (live, attenuated) not less than 19,400 PFU produced in human diploid (MRC-5) cells PFU = Plaque-forming units 
1, sev Oka/Merck, (živ, atenuiran) ne manj kot 19.400 PFU pridobljen na humanih diploidnih (MRC-5) celicah PFU (Plaque-forming units) = enote, ki tvorijo plak
After reconstitution, the vaccine should be used immediately. 
Cepivo je treba uporabiti nemudoma po rekonstituciji.
Do not use this vaccine after the expiry date which is stated on the outer carton after EXP. 
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake EXP. Rok uporabnosti cepiva se izteče na zadnji dan navedenega meseca.
, Swelling Injection site: Induration 1, Haematoma 
, otekanje na mestu injiciranja: zatrdlina 1, hematom toplota
Ophthalmic zoster occurred in 35 subjects vaccinated with ZOSTAVAX vs. 69 subjects who received placebo. 
Herpes zoster ophthalmicus se je pojavil pri 35 osebah, ki so bile cepljene s cepivom ZOSTAVAX, in 69 osebah, ki so prejele placebo.
In any case, pregnancy should be avoided for one month following vaccination (see section 4.3). 
Vsekakor pa ženska ne sme zanositi 1 mesec po cepljenju (glejte poglavje 4.3).
In SPS and ZEST, the number of subjects who reported herpes zoster/herpes zoster-like rashes was less than 0.2% for ZOSTAVAX and placebo groups, with no significant difference observed between the two groups. 
V študijah SPS in ZEST je bil delež oseb, pri katerih so poročali o herpesu zostru/herpesu zostru podobnih izpuščajih, manjši od 0,2 % pri cepivu ZOSTAVAX in pri placebu, brez pomembnih razlik med obema skupinama.
Across all other clinical trials, the Oka/Merck strain was identified by PCR analysis from the lesion specimens of only two subjects who reported varicella-like rashes (onset on Day 8 and 17). 
Skupno so v vseh drugih kliničnih preskušanjih s PCR analizo sev Oka/Merck zaznali le v vzorcih lezij, ki so pripadali dvema osebama, pri katerih so poročali o noricam podobnih izpuščajih (s pričetkom 8. in 17. dne).
During the course of the STPS, placebo recipients were offered ZOSTAVAX, at which time they were considered to have completed the STPS. 
Med študijo STPS so prejemnikom placeba ponudili cepivo ZOSTAVAX, s čimer se je štelo, da so zaključili sodelovanje v študiji STPS.
For storage conditions after reconstitution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po rekonstituciji cepiva glejte poglavje 6.3.
For precautions to be taken before handling or administering the medicinal product see section 6.6. 
Za previdnostne ukrepe potrebne pred ravnanjem s cepivom ali dajanjem cepiva glejte poglavje 6.6.
• Immunosuppressive therapy (including high-dose corticosteroids) (see sections 4.4 and 4.8); however, ZOSTAVAX is not contraindicated for use in individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or in patients who are receiving corticosteroids as replacement therapy, e.g., for adrenal insufficiency (see sections 4.8 and 5.1). 
• Imunosupresivno zdravljenje (vključno z visokimi odmerki kortikosteroidov) (glejte poglavji 4.4 in 4.8), vendar pa uporaba cepiva ZOSTAVAX ni kontraindicirana pri osebah, ki se zdravijo z lokalnimi/inhalacijskimi kortikosteroidi ali nizkimi odmerki sistemskih kortikosteroidov ali pa prejemajo kortikosteroide kot nadomestno zdravljenje, npr. v primeru insuficience nadledvične žleze (glejte poglavji 4.8 in 5.1).
However naturally-occurring varicella-zoster virus infection is known to sometimes cause foetal harm. 
Znano pa je, da naravna okužba z virusom varicella-zoster včasih škoduje razvoju ploda.
§ Age-adjusted estimate based on the age strata (60-69 and ≥70 years of age) at randomisation. 
§ Starostno prilagojene ocene na podlagi starostnih stratumov (60-69 in ≥ 70 let) ob randomizaciji
In subjects who developed zoster, ZOSTAVAX decreased the risk of subsequently developing PHN. 
Pri osebah, pri katerih se je pojavil herpes zoster, je cepivo ZOSTAVAX zmanjšalo tveganje za poznejši pojav PHN.
VZV was detected in one (0.01%) specimen from a ZOSTAVAX recipient reporting a varicella/varicella-like rash; however, the virus strain (wild type or Oka/Merck strain) could not be determined. 
VZV so zaznali v enem (0,01 %) vzorcu, ki je pripadal prejemniku cepiva ZOSTAVAX, pri katerem so poročali o noricah/noricam podobnem izpuščaju, vendar virusnega seva (divjega tipa ali seva Oka/Merck) ni bilo mogoče določiti.
The protective clinical efficacy of ZOSTAVAX was demonstrated in two large, randomised, placebo controlled clinical trials where subjects received ZOSTAVAX subcutaneously (see Tables 2 and 3). 
Klinično učinkovitost zaščite cepiva ZOSTAVAX so dokazali v dveh velikih, randomiziranih, s placebom nadzorovanih kliničnih preskušanjih, v katerih so osebe cepivo ZOSTAVAX prejele subkutano (glejte preglednici 2 in 3).
• Primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukaemias; lymphoma; other conditions affecting the bone marrow or lymphatic system; immunosuppression due to HIV/AIDS (see sections 4.4, 4.8 and 5.1); cellular immune deficiencies. 
• Dedne in pridobljene imunske pomanjkljivosti zaradi stanj, kot so: akutne in kronične levkemije, limfomi, druga stanja, ki prizadenejo kostni mozeg ali limfatični sistem, imunosupresija zaradi okužbe z virusom HIV/AIDS (glejte poglavja 4.4, 4.8 in 5.1) in celična imunska pomanjkljivost.
Fertility ZOSTAVAX has not been evaluated in fertility studies. 
Plodnost Cepivo ZOSTAVAX ni bilo ocenjeno v študijah plodnosti.
What ZOSTAVAX is and what it is used for What you need to know before you receive ZOSTAVAX How to use ZOSTAVAX 
Kaj je cepivo ZOSTAVAX in za kaj ga uporabljamo Kaj morate vedeti, preden boste cepljeni s cepivom ZOSTAVAX Kako uporabljati cepivo ZOSTAVAX Možni neželeni učinki
VZV-specific immune responses were generally similar in subjects 50 to 59 compared to subjects ≥60 years of age. 
Za VZV specifični imunski odziv je bil pri 50 do 59 let starih osebah v splošnem podoben kot pri osebah, starih ≥ 60 let.
As with many vaccines, ZOSTAVAX may not completely protect all persons who are vaccinated. 
Kot pri mnogih cepivih tudi pri cepivu ZOSTAVAX obstaja možnost, da vse cepljene osebe ne bodo popolnoma zaščitene.
Persistence of ZOSTAVAX efficacy was studied 4 to 7 years post-vaccination in the STPS, which included 7,320 subjects previously vaccinated with ZOSTAVAX and 6,950 subjects previously vaccinated with placebo in the SPS (mean age at enrollment was 73.3 years); and 7 to 10 years postvaccination in the Long-term Persistence Substudy (LTPS), which included 6,867 subjects previously vaccinated with ZOSTAVAX (mean age at enrollment into the LTPS was 74.5 years). 
Trajanje učinkovitosti cepiva ZOSTAVAX je bilo preučevano v obdobju od 4 do 7 let po cepljenju v študiji STPS, ki je zajela 7.320 oseb, predhodno cepljenih s cepivom ZOSTAVAX, in 6.950 oseb, predhodno cepljenih s placebom, v študiji SPS (povprečna starost ob vključitvi je bila 73,3 leta) ter v obdobju od 7 do 10 let po cepljenju v študiji LTPS, ki je zajela 6.867 oseb, predhodno cepljenih s cepivom ZOSTAVAX (povprečna starost ob vključitvi v študijo LTPS je bila 74,5 let).
1, Oka/Merck strain, (live, attenuated) not less than 19,400 PFU (plaque-forming units). 
1, sev Oka/Merck, (živ, oslabljen), ne manj kot 19.400 enot, ki tvorijo plak (PFU - plaque-forming units).
Marketing Authorisation Holder and Manufacturer 
Imetnik dovoljenja za promet s cepivom in izdelovalec
ZOSTAVAX is indicated for prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN). 
Cepivo ZOSTAVAX je indicirano za preprečevanje herpesa zostra (“zoster” ali pasovec) in z njim povezane postherpetične nevralgije (PHN - post-herpetic neuralgia).
ZOSTAVAX is given as a single dose. 
Cepivo ZOSTAVAX se daje v obliki enkratnega odmerka.
Reconstitution instructions 
Navodila za rekonstitucijo
If you have a blood clotting disorder or low levels of platelets, the vaccine should be given under the skin because bleeding may occur following administration into the muscle. 
Če imate motnjo strjevanja krvi ali nizko raven trombocitov, je treba cepivo injicirati pod kožo, ker se po injiciranju v mišico lahko pojavi krvavitev.
Immunisation should be postponed in individuals suffering from moderate to severe acute febrile illness or infection. 
Cepljenje je treba odložiti pri osebah z zmerno do hudo akutno boleznijo ali okužbo s povišano telesno temperaturo.
• if you have a fever 
• če imate zvišano telesno temperaturo,
Disease information on shingles: 
Informacije o pasovcu:
† VE was estimated for the first episode of herpes zoster during follow-up and was calculated as (1-hazards ratio)*100 * Cox models adjusted for calendar time, age, sex, race/ethnic group, healthcare resource utilization (flu vaccination, number of weeks with an outpatient visit per year), co-morbid conditions (DxCG score, HCUP risk score), immunocompromise status during follow-up ‡ VE over study period is the VE calculated over the full duration of the study (2007-2014) at the time of this interim analysis § Average VE was calculated as the weighted average of the annual VE estimates over 3 and 5 years, respectively, where the weights are the proportion of the overall time period covered ¶ Data not available 
† VE je bila ovrednotena pri prvem izbruhu herpes zostra med spremljanjem in je bila izračunana kot (1-razmerje ogroženosti)*100 * Coxovi modeli prilagojeni za koledarski čas, starost, spol, raso/etnično skupino, porabo sredstev zdravstvenega varstva (cepljenje proti gripi, število tednov z ambulantnim obiskom v enem letu), sočasna bolezenska stanja (vrednost DxCG, ocena tveganja HCUP), stanje imunske oslabelosti med spremljanjem ‡ VE v obdobju študije je VE izračunana v času te vmesne analize za celotno trajanje študije (2007-2014) § Povprečna VE je bila izračunana kot uteženo povprečje ocen letne VE v času 3 in 5 let, kjer so uteži delež celotnega zajetega časovnega obdobja ¶ Podatki niso na voljo.
‡ Age strata at randomisation were 60-69 and ≥70 years of age. 
† Starostna stratuma ob randomizaciji sta bila 60-69 in ≥ 70 let.
VE estimates by age at vaccination and average VE estimates over the first 3 and 5 years postvaccination are shown below (see Table 6). 
Vrednosti VE glede na starost ob cepljenju ter povprečne vrednosti VE v obdobju prvih 3 in 5 let po cepljenju so prikazane spodaj (glejte preglednico 6).
• Common (may affect up to 1 in 10 people): Warmth, bruising, hard lump, and rash at the injection site*; headache*; pain in the arm or leg*; joint pain, muscle pain; fever; rash 
• Pogosti (pojavijo se lahko pri največ 1 od 10 oseb): občutek toplote, modrice, zatrdlina in izpuščaj na mestu injiciranja*; glavobol*; bolečina v roki ali nogi*; bolečina v sklepih, bolečina v mišicah; zvišana telesna temperatura; izpuščaj
• History of hypersensitivity to the active substance, to any of the excipients or trace residuals (e.g. neomycin) (see sections 4.4 and 6.1). 
• Anamneza preobčutljivosti na učinkovino, katero koli pomožno snov ali v sledeh prisotne snovi (npr. neomicin) (glejte poglavji 4.4 in 6.1).
Overall, among vaccinated individuals who developed zoster, ZOSTAVAX significantly reduced overall acute and chronic zoster-associated pain compared with placebo. 
Skupno je med cepljenimi posamezniki, pri katerih se je pojavil herpes zoster, cepivo ZOSTAVAX pomembno zmanjšalo skupno akutno in kronično bolečino, povezano s herpesom zostrom, v primerjavi s placebom.
It is important to use a separate sterile syringe and needle for each patient to prevent transmission of infectious agents from one individual to another. 
Pomembno je, da pri cepljenju vsake posamezne osebe uporabite novo injekcijsko brizgo in iglo in tako preprečite širjenje povzročiteljev okužb.
* The table is based on the Modified Intent-To-Treat (MITT) population that included all subjects randomised in the study who were followed for at least 30 days post-vaccination and did not develop an evaluable case of zoster within the first 30 days post-vaccination. 
* Preglednica temelji na modificirani populaciji z-namenom-zdravljenja (MITT), ki je zajela vse osebe, ki so bile randomizirane v študijo in so jih spremljali vsaj 30 dni po cepljenju ter se jim v prvih 30 dneh po cepljenju ni pojavil ocenljiv primer herpesa zostra.
As for any vaccine, vaccination with ZOSTAVAX may not result in protection in all vaccine recipients. 
Kot velja za vsa cepiva, tudi cepivo ZOSTAVAX morda ne bo zaščitilo vseh cepljenih oseb.
ZOSTAVAX is a vaccine used to prevent shingles (zoster) and zoster-related post-herpetic neuralgia (PHN), the long-lasting nerve pain that follows shingles. 
ZOSTAVAX je cepivo, ki se uporablja za preprečevanje pasovca (herpesa zostra) in z njim povezane postherpetične nevralgije (PHN), dolgotrajne bolečine živca, ki sledi pasovcu.
One pack of ZOSTAVAX contains a vial and a pre-filled syringe with or without attached needles. 
Eno pakiranje cepiva ZOSTAVAX vsebuje vialo in napolnjeno injekcijsko brizgo s pritrjeno iglo ali brez nje.
Number of PHN cases 
Št. primerov PHN
Incidence rate of PHN per person years 
Delež pojavnosti PHN na oseb-let
• Very common (may affect more than 1 in 10 people): Redness, pain, swelling and itching at the injection site* 
• Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 oseb): rdečina, bolečina, otekanje in srbenje na mestu injiciranja*
VE estimates by age at vaccination and average VE estimates over the first 3 and 5 years postvaccination are shown below (see Table 7). 
Vrednosti VE glede na starost ob cepljenju ter povprečne vrednosti VE v obdobju prvih 3 in 5 let po cepljenju so prikazane spodaj (glejte preglednico 7).
Based on limited data from 2 clinical trials that enrolled VZV-seronegative or low seropositive subjects (30 years of age or older) receiving live attenuated zoster vaccine, injection site and systemic adverse experiences were generally similar to those reported by other subjects who received ZOSTAVAX in clinical trials, with 2 of the 27 subjects reporting fever. 
Na podlagi maloštevilnih podatkov iz 2 kliničnih preskušanj, v katera so bile vključene VZV-seronegativne osebe in nizko seropozitivne osebe (stare 30 let ali več), ki so prejele živo, atenuirano cepivo proti herpesu zostru, so bili neželeni učinki na mestu injiciranja in sistemski neželeni učinki na splošno podobni tistim pri drugih osebah, ki so prejele cepivo ZOSTAVAX v kliničnih preskušanjih, pri čemer so pri 2 od 27 oseb poročali o zvišani telesni temperaturi.
After reconstitution, 1 dose (0.65 mL) contains: The active substance is: 
Po rekonstituciji 1 odmerek (0,65 ml) vsebuje: Učinkovina je:
• Very rare (may affect up to 1 in 10,000 people): Varicella (chicken pox); shingles; damage of retina caused by inflammation resulting in changes in sight (in patients under immunosuppressive therapy). 
• Zelo redki (pojavijo se lahko pri največ 1 od 10.000 oseb): norice; pasovec; poškodba očesne mrežnice zaradi vnetja, ki povzroči spremembe vida (pri bolnikih, ki prejemajo zdravila za zaviranje imunskega odziva)